LeMaitre Vascular Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de LeMaitre Vascular de 13% y 7% por año respectivamente. Se prevé que el BPA crezca en un 12.1% al año. Se espera que la rentabilidad financiera sea de 12.8% en 3 años.

Información clave

12.7%

Tasa de crecimiento de los beneficios

11.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	17.5%
Tasa de crecimiento de los ingresos	7.6%
Rentabilidad financiera futura	13.3%
Cobertura de analistas	Good
Última actualización	20 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

Sep 17

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

Sep 04

If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

Aug 22

LeMaitre Vascular: A Small Cap With Best-In-Industry Growth

Jul 23

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Jul 12

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Mar 12

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Oct 23

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oct 05

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

Sep 13

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

Sep 08

LeMaitre Vascular goes ex dividend tomorrow

Aug 23

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:LMAT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	256	54	60	58	6
12/31/2025	237	47	52	54	9
12/31/2024	218	42	37	46	9
6/30/2024	206	38	32	37	N/A
3/31/2024	200	34	33	40	N/A
12/31/2023	193	30	29	37	N/A
9/30/2023	186	27	23	30	N/A
6/30/2023	177	25	19	26	N/A
3/31/2023	169	21	18	23	N/A
12/31/2022	162	21	22	25	N/A
9/30/2022	160	21	24	26	N/A
6/30/2022	160	22	29	33	N/A
3/31/2022	158	27	29	34	N/A
12/31/2021	154	27	30	35	N/A
9/30/2021	152	28	39	44	N/A
6/30/2021	151	29	40	44	N/A
3/31/2021	135	24	37	40	N/A
12/31/2020	129	21	32	35	N/A
9/30/2020	122	19	23	26	N/A
6/30/2020	115	16	13	17	N/A
3/31/2020	119	18	12	16	N/A
12/31/2019	117	18	10	14	N/A
9/30/2019	115	19	12	15	N/A
6/30/2019	111	18	12	15	N/A
3/31/2019	108	23	12	16	N/A
12/31/2018	106	23	16	20	N/A
9/30/2018	103	21	16	20	N/A
6/30/2018	104	22	18	24	N/A
3/31/2018	103	18	N/A	24	N/A
12/31/2017	101	17	N/A	23	N/A
9/30/2017	98	15	N/A	20	N/A
6/30/2017	96	14	N/A	18	N/A
3/31/2017	93	12	N/A	18	N/A
12/31/2016	89	11	N/A	17	N/A
9/30/2016	86	11	N/A	17	N/A
6/30/2016	82	9	N/A	14	N/A
3/31/2016	79	9	N/A	13	N/A
12/31/2015	78	8	N/A	11	N/A
9/30/2015	76	7	N/A	10	N/A
6/30/2015	74	6	N/A	9	N/A
3/31/2015	73	5	N/A	7	N/A
12/31/2014	70	4	N/A	6	N/A
9/30/2014	70	3	N/A	4	N/A
6/30/2014	67	3	N/A	4	N/A
3/31/2014	65	2	N/A	4	N/A
12/31/2013	64	3	N/A	5	N/A
9/30/2013	61	3	N/A	4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13% al año) de LMAT es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (13% al año) de LMAT crezcan menos que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de LMAT crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (7.1% al año) de LMAT crezcan más despacio que el mercado de US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.1% al año) de LMAT crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LMAT sea baja dentro de 3 años (12.8%).

LeMaitre Vascular Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Price target increased by 10% to US$71.29

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Price target increased by 9.0% to US$62.33

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Recent updates

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on August 29, 2024

LeMaitre Vascular: A Small Cap With Best-In-Industry Growth

LeMaitre Vascular, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

Independent Director notifies of intention to sell stock

President & Director recently sold US$380k worth of stock

Chairman & CEO notifies of intention to sell stock

First quarter dividend of US$0.16 announced

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

LeMaitre Vascular, Inc. to Report Q1, 2024 Results on May 02, 2024

LeMaitre Vascular, Inc., Annual General Meeting, Jun 03, 2024

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Now 22% undervalued

Chairman & CEO exercised options to buy US$983k worth of stock.

Now 22% undervalued

Chairman & CEO recently sold US$6.9m worth of stock

Upcoming dividend of US$0.16 per share

Chairman & CEO notifies of intention to sell stock

Fourth quarter dividend increased to US$0.16

Price target increased by 10% to US$71.29

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Full year 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. (NasdaqGM:LMAT) announces an Equity Buyback for $50 million worth of its shares.

LeMaitre Vascular, Inc. to Report Q4, 2023 Results on Feb 27, 2024

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Chairman & CEO exercised options to buy US$961k worth of stock.

Chairman & CEO recently sold US$2.8m worth of stock

Chairman & CEO notifies of intention to sell stock

Independent Director exercised options to buy US$395k worth of stock.

Chairman & CEO exercised options to buy US$680k worth of stock.

Upcoming dividend of US$0.14 per share at 1.1% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

LeMaitre Vascular, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 18%

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Upcoming dividend of US$0.14 per share at 1.0% yield

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. to Report Q2, 2023 Results on Aug 01, 2023

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Independent Director notifies of intention to sell stock

Chairman & CEO recently sold US$445k worth of stock

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Chairman & CEO notifies of intention to sell stock

President & Director recently sold US$555k worth of stock

Investor sentiment improves as stock rises 22%

Chairman & CEO notifies of intention to sell stock

Price target increased by 9.0% to US$62.33

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Senior Vice President of Operations notifies of intention to sell stock

President & Director exercised options and sold US$258k worth of stock

Upcoming dividend of US$0.14 per share at 1.1% yield

Full year 2022 earnings released: EPS: US$0.94 (vs US$1.27 in FY 2021)

LeMaitre Vascular, Inc. to Report Q4, 2022 Results on Feb 23, 2023

President & Director exercised options to buy US$145k worth of stock.